Biocon Limited has informed the Exchange regarding a press release dated October 01, 2025, titled "Biocon Biologics Secures U.S. Market Entry Date for Bosaya and Aukelso , Denosumab Biosimilars".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited's subsidiary, Biocon Biologics, has secured a U.S. market entry date for two of its Denosumab biosimilars, branded as Bosaya and Aukelso. Denosumab is a widely used biologic for treating osteoporosis and bone-related conditions, originally marketed by Amgen as Prolia and Xgeva. Securing a confirmed U.S. launch date is a key regulatory and commercial milestone, clearing the path for sales in the world's largest pharmaceutical market. This marks an important expansion of Biocon Biologics' biosimilar portfolio into the U.S., a high-value territory for specialty biologics. The development signals progress in the company's strategy to globalize its biosimilars business and compete in the lucrative bone-health therapy segment.
This is a positive development for Biocon shareholders, as it paves the way for a new revenue stream from the U.S. market. The Denosumab biosimilar segment offers significant commercial potential, and a confirmed entry date reduces regulatory uncertainty, likely supporting investor confidence in Biocon Biologics' growth trajectory.